Herbo-mineral ayurvedic treatment in a high risk acute promyelocytic leukemia patient with second relapse: 12 years follow up

Journal of Ayurveda and Integrative Medicine

Volumn 1, Issue 3, 2010, Pages 215-218

  Prakash, Balendu ^a   Parikh, Purvish M ^b   Pal, Sanjoy K ^c  

^a V C P Cancer Research Foundation (Scientific and Industrial Research Organization)   (India)

^b AmeriCares India   (India)

^c 142 AB Kandivali Industrial Estate   (India)

Author keywords

Ayurveda; herbo mineral; relapse acute promyelocytic leukemia

Indexed keywords

AMRTA SATVA; ANTIBIOTIC AGENT; AYURVEDIC DRUG; CHANDAN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FRESH FROZEN PLASMA; GOJIHVA; GRANULOCYTE COLONY STIMULATING FACTOR; GULAB; IDARUBICIN; JAHARMOHRA; KAMDUDHA RAS; KAPARDIKA BHASMA; KEHRUBA PISTI; LATA KASTURI; MAUKTIK PISHTI; MITOXANTRONE; MUKTA SUKTI PISTI; MYELOPEROXIDASE; NAVJEEVAN; NIRVISHA; PRAVALA PISTI; RAJAT BHASMA; RETINOIC ACID; SVARNA GAIRIKA; TARUNI; TRINAKANTA MANI CHURNA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; AYURVEDA; BASOPHIL; BLOOD TRANSFUSION; BONE MARROW BIOPSY; BRONCHOSPASM; CANCER SURVIVAL; CASE REPORT; CONSERVATIVE TREATMENT; DIABETES MELLITUS; DISEASE FREE SURVIVAL; DRUG ANALYSIS; DRUG TOLERABILITY; EOSINOPHIL COUNT; ERYTHROPOIESIS; FEVER; HIGH RISK PATIENT; HUMAN; LEUKEMIA RELAPSE; LYMPHOCYTE COUNT; MALE; MEGAKARYOCYTE; MONOCYTE; MULTIPLE CYCLE TREATMENT; MYELOPOIESIS; NEUTROPHIL COUNT; ODYNOPHAGIA; PRIORITY JOURNAL; PROMYELOCYTE; PROMYELOCYTIC LEUKEMIA; REMISSION; UNSPECIFIED SIDE EFFECT; VOMITING; WEAKNESS;

EID: 79952936924     PISSN: 09759476     EISSN: 09762809     Source Type: Journal    
DOI: 10.4103/0975-9476.72618     Document Type: Article

References (11)

1. Fukai Y, Hirata M, Ueno M, Ichikawa N, Kobayashi H, Saitoh H, et al. Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: Speciation of arsenic metabolites in serum and urine. Biol Pharm Bull 2006;29:1022-7.
2. Dutta P, Sazawal S, Kumar R, Saxena R. Does acute promyelocytic leukemia in Indian patients have biology different from the West? Indian J Pathol Microbiol 2008;51:431-9.
3. Estey E. Prognostic factors in acute myelogenous leukemia. Leukemia 2001;15: 670-2. (Pubitemid 32266742)
4. Wheatley K, Burnett A, Goldstone A, Gray R, Hann I, Harrison C, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial: United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999;107:69-79. (Pubitemid 29500811)
5. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, et al. Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009;113:1875-91.
6. Lo-Coco F, Ammatuna E, Montesinos P, Sanz MA. Acute promyelocytic leukemia: Recent advances in diagnosis and management. Semin Oncol 2008;35:401-9.
7. Tallman MS. Treatment of relapsed or refractory acute promyelocytic leukemia. Best Pract Res Clin Haematol 2007;20:57-65.
8. Prakash B. Indigenous approach to combat cancer. Health Administrator 2005;17:169-71.
9. Effect of metal based Ayurvedic formulations in the patients of acute pro-myelocytic leukemia (APML): A pilot study. Prepared by Central Council for Ayurvedic Research in Ayurveda and Siddha, Department of AYUSH, Ministry of Health and Family Welfare, Government of India, New Delhi. Available from: http://www.padaav.com/content/Monograph.pdf. [Last accessed on 2010 Sept 1].
10. Kumar P, Bhattacharyya GS, Dattatreya S, Malhotra H. Tackling the cancer Tsunami. Indian J Cancer 2009;46:1-4.
11. Gupta M, Shafiq N, Kumari S, Pandhi P. Pattern and perception of complementary and alternative medicine (CAM) among leukemia patients visiting haematology clinic of a north Indian tertiary care hospital. Pharmacoepidemiol Drug Saf 2002;11:671-6. (Pubitemid 35469362)